Singh Niti, Sidiq Zeeshan, Bhalla Manpreet, Myneedu V P, Sarin Rohit
Indian J Tuberc. 2014 Apr;61(2):148-51.
Tuberculosis (TB) remains a major global health problem and ranks as the second leading cause of death worldwide. An important cause of TB epidemic is the emergence of multi drug resistant (MDR) strains of Mycobacterium tuberculosis. Despite the availability of treatment that is expected to cure most cases of TB, levels of MDR-TB remain worryingly high in India.
This study was carried out to ascertain the prevalence of MDR-TB among category I pulmonary TB treatment failure patients.
This was a retrospective study involving 750 pulmonary tuberculosis patients enrolled at six district centres of Delhi State under RNTCP who failed to respond to CAT I treatment and whose sputum samples were submitted for culture and drug sensitivity testing (DST) over a period of three years (2009-2012). MDR-TB was defined as TB caused by bacilli showing resistance to at least isoniazid and rifampicin.
Out of the total 750 patients included in the study, 470 (62.6 %) were culture positive. Of these, 377 (80.2%) were subjected to DST and rest 93 (19.7%) were excluded. Ultimately, DST result was available for 353 (93.6 %) cases. 239 (68%) cases were detected as multi drug resistant TB.
High proportion of MDR-TB (68%) among culture positive CAT I treatment failure cases highlights the need for rapid diagnostic tests which will enable the detection of MDR-TB at an early stage and will thus minimize the risk of transmission as well as the possible errors associated with the treatment.
结核病仍然是一个重大的全球健康问题,是全球第二大死因。结核病流行的一个重要原因是结核分枝杆菌多重耐药(MDR)菌株的出现。尽管有预期能治愈大多数结核病病例的治疗方法,但印度的耐多药结核病水平仍然高得令人担忧。
本研究旨在确定I类肺结核治疗失败患者中耐多药结核病的患病率。
这是一项回顾性研究,涉及德里邦六个地区中心根据国家结核病控制规划登记的750例肺结核患者,这些患者对I类治疗无反应,其痰标本在三年(2009 - 2012年)期间被送去进行培养和药敏试验(DST)。耐多药结核病被定义为由对至少异烟肼和利福平耐药的杆菌引起的结核病。
在纳入研究的750例患者中,470例(62.6%)培养呈阳性。其中,377例(80.2%)进行了药敏试验,其余93例(19.7%)被排除。最终,353例(93.6%)病例获得了药敏试验结果。239例(68%)病例被检测为耐多药结核病。
I类治疗失败且培养呈阳性的病例中耐多药结核病比例较高(68%),这突出表明需要快速诊断测试,以便能够在早期检测出耐多药结核病,从而将传播风险以及与治疗相关的可能错误降至最低。